<DOC>
	<DOCNO>NCT00429299</DOCNO>
	<brief_summary>Evaluate activity Trastuzumab , Lapatinib , combination agent chemotherapy preoperative ( neoadjuvant ) treatment early breast cancer .</brief_summary>
	<brief_title>Neoadjuvant Study With Chemotherapy , Lapatinib And Trastuzumab In Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Inclusion criterion : Histologically confirm infiltrate primary breast cancer &gt; 2.0 cm large clinical diameter HER2 positive tumor ( either IHC 3+ FISH+ ) Availability tumor tissue suitable biological molecular examination start primary treatment Age &gt; 18 , &lt; 65 year ECOG PS 01 Normal organ marrow function define : leukocyte ³ 3000/microL absolute neutrophil count ³ 1,500/microL platelet ³ 100,000/microL total bilirubin &lt; = 1.5x ULN . In case Gilbert 's syndrome , &lt; 2 x ULN allow AST ( SGOT ) /ALT ( SGPT ) &lt; = 2.5 X institutional upper limit normal Alkaline phosphatase &lt; = 2.5 x ULN Creatinine within normal institutional limit Cardiac ejection fraction within institutional range normal measure echocardiogram MUGA scan Eligibility patient receive medication substance know affect , potential affect activity pharmacokinetics lapatinib determine follow review use Principal Investigator . A list medication substance know potential interact CYP450 isoenzymes provide The effect lapatinib develop human fetus recommend therapeutic dose unknown ; woman childbearing potential must agree use adequate contraception ( hormonal barrier method birth control abstinence ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately , patient apprise potential hazard fetus potential risk loss pregnancy Ability understand willingness sign write informed consent document Ability swallow retain oral medication Exclusion criterion : Stage IIIB , IIIC , inflammatory breast cancer Stage IV breast cancer Contraindication treatment anthracycline , paclitaxel and/or trastuzumab Prior treatment chemotherapy , endocrine therapy radiotherapy . Prior treatment EGFR target therapy Treatment investigational agent , herbal ( alternative ) medicine History allergic reaction attribute compound similar chemical biologic composition lapatinib Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Pregnancy breastfeeding ; ( breast feed discontinue enrolled study ) Women childbearing potential refusal adopt adequate contraceptive measure HIVpositive patient receive combination antiretroviral therapy GI tract disease result inability take oral medication , malabsorption syndrome , requirement IV alimentation , prior surgical procedure affect absorption , uncontrolled inflammatory GI disease ( e.g. , Crohn 's , ulcerative colitis ) Concomitant requirement medication classify CYP3A4 inducer inhibitor</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>neo-adjuvant trastuzumab early breast cancer lapatinib</keyword>
</DOC>